These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 6860565)

  • 1. Altered polymorphonuclear leukocyte responses in psoriasis: chemotaxis and degranulation.
    Preissner WC; Schröder JM; Christophers E
    Br J Dermatol; 1983 Jul; 109(1):1-8. PubMed ID: 6860565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic leukotriene B4 is a potent chemotaxin but a weak secretagogue for human PMN.
    Rollins TE; Zanolari B; Springer MS; Guindon Y; Zamboni R; Lau CK; Rokach J
    Prostaglandins; 1983 Feb; 25(2):281-9. PubMed ID: 6304818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivities of purified human eosinophils and neutrophils to defined chemotaxins.
    Morita E; Schröder JM; Christophers E
    Scand J Immunol; 1989 Jun; 29(6):709-16. PubMed ID: 2544988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient absence of C5a-specific neutrophil function in inflammatory disorders of the skin.
    Schröder JM; Christophers E
    J Invest Dermatol; 1985 Sep; 85(3):194-8. PubMed ID: 3161955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils.
    Schröder JM; Kosfeld U; Christophers E
    J Invest Dermatol; 1985 Jul; 85(1):30-4. PubMed ID: 2989375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphonuclear leukocyte function in psoriasis: chemotaxis, chemokinesis, beta-adrenergic receptors, and proteolytic enzymes of polymorphonuclear leukocytes in the peripheral blood from psoriatic patients.
    Fräki JE; Jakoi L; Davies AO; Lefkowitz RJ; Snyderman R; Lazarus GS
    J Invest Dermatol; 1983 Sep; 81(3):254-7. PubMed ID: 6309987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotactic factor-induced effects upon deformability of human polymorphonuclear leukocytes.
    Kawaoka EJ; Miller ME; Cheung AT
    J Clin Immunol; 1981 Jan; 1(1):41-4. PubMed ID: 7334069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of filter-bound IgA in inhibiting polymorphonuclear leukocyte chemotaxis.
    Schröder JM; Christophers E
    Immunobiology; 1983 Mar; 164(2):127-35. PubMed ID: 6852861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid induced degranulation of rabbit neutrophils.
    Naccache PH; Volpi M; Becker EL; Makryannis A; Sha'afi RI
    Biochem Biophys Res Commun; 1982 Jun; 106(4):1286-90. PubMed ID: 6288043
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of human neutrophil chemotaxis by the protein kinase inhibitor, 1-(5-isoquinolinesulfonyl) piperazine.
    Harvath L; McCall CE; Bass DA; McPhail LC
    J Immunol; 1987 Nov; 139(9):3055-61. PubMed ID: 2822802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wheat germ agglutinin specifically inhibits formyl peptide-induced polymorphonuclear leukocyte chemotaxis.
    Perez HD; Ong R; Khanna K; Banda D; Goldstein IM
    J Immunol; 1982 Dec; 129(6):2718-24. PubMed ID: 6897258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.
    Charo IF; Yuen C; Perez HD; Goldstein IM
    J Immunol; 1986 May; 136(9):3412-9. PubMed ID: 3514759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the respiratory burst enzyme in human polymorphonuclear leukocytes by chemoattractants and other soluble stimuli. Evidence that the same oxidase is activated by different transductional mechanisms.
    McPhail LC; Snyderman R
    J Clin Invest; 1983 Jul; 72(1):192-200. PubMed ID: 6409928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cell surface contact in the kinetics of superoxide production by granulocytes.
    Dahinden CA; Fehr J; Hugli TE
    J Clin Invest; 1983 Jul; 72(1):113-21. PubMed ID: 6308042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation.
    Solomkin JS; Jenkins MK; Nelson RD; Chenoweth D; Simmons RL
    Surgery; 1981 Aug; 90(2):319-27. PubMed ID: 7256544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deactivation of human neutrophil chemotaxis by chemoattractants: effect on receptors for the chemotactic factor f-Met-Leu-Phe.
    Donabedian H; Gallin JI
    J Immunol; 1981 Sep; 127(3):839-44. PubMed ID: 6790618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells.
    Colotta F; Orlando S; Fadlon EJ; Sozzani S; Matteucci C; Mantovani A
    J Exp Med; 1995 Jun; 181(6):2181-6. PubMed ID: 7760005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor or colchicine.
    Anderson DC; Hughes BJ; Smith CW
    J Clin Invest; 1981 Oct; 68(4):863-74. PubMed ID: 7287906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3a-induced lysosomal enzyme secretion from human neutrophils: lack of inhibition by f met-leu-phe antagonists and inhibition by arachidonic acid antagonists.
    Showell HJ; Glovsky MM; Ward PA
    Int Arch Allergy Appl Immunol; 1982; 67(3):227-32. PubMed ID: 6800960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cytochalasin B to distinguish between early and late events in neutrophil activation.
    Bennett JP; Cockcroft S; Gomperts BD
    Biochim Biophys Acta; 1980 Oct; 601(3):584-91. PubMed ID: 6251879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.